Tech Times on MSN

Teva's $420M Samsung Bioepis deal includes biosimilar banned from US until 2029 patent expires

Samsung Bioepis Teva biosimilar deal announced Monday grants Teva exclusive US rights to two FDA-approved drugs -- RENFLEXIS ...
ascopubs.org

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study Convincing data support the link ...
The American Journal of Managed Care

Drug Survival of Biosimilars, Originator TNF Inhibitors Similar

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...
Healio

Biosimilars, originators discontinued at similar rates for inefficacy, adverse events

Please provide your email address to receive an email when new articles are posted on . TNF inhibitors and their biosimilars showed no significant differences in risk for discontinuation due to ...
Medscape

TNF-alpha Inhibitors Linked to Lower Risk for Primary Open-Angle Glaucoma

The use of TNF-alpha inhibitors is associated with a lower risk of developing primary open-angle glaucoma and requiring certain glaucoma treatments, a study finds.
Business Wire

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related ...
Business Wire

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, ...